Report

Update: Termination of coverage

Edison Investment Research is terminating coverage on Arrowhead Research (ARWR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Underlying
Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, the company's therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. The company is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The company's pipeline includes, among others, ARO-AAT, a candidate for the treatment of liver disease, and ARO-APOC3, which is designed to reduce production of Apolipoprotein C-III, a component of triglyceride rich lipoproteins.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch